The Capitello 281 study established PTEN deficiency not just as a biomarker, but as a distinct subpopulation of prostate cancer. This subtype has a poor prognosis, higher rates of symptomatic bone complications, and often progresses with a relatively low Prostate-Specific Antigen (PSA), making it biologically distinct from other prostate cancers.
A key challenge in managing patients with PTEN loss is the observed discordance between rising PSA levels and actual disease progression. Some patients progress radiographically with minimal or no PSA change, suggesting that traditional PSA surveillance is insufficient and that systematic imaging may be necessary for this specific subpopulation.
Clinicians experience significant anxiety managing patients who fail to achieve a deep PSA response (e.g., <0.2 ng/mL), even with aggressive initial therapy. This "waiting for the shoe to drop" scenario creates a strong desire to proactively add new agents, like an AKT inhibitor, outside of standard guidelines to preempt an anticipated poor outcome.
Experts advocate for using AKT inhibitors in the early, hormone-sensitive setting for PTEN-deficient prostate cancer. The rationale is that early-stage disease is more dependent on the AKT pathway. In later, castrate-resistant stages, the cancer develops other resistance mechanisms and alterations, diminishing the potential impact of a targeted AKT inhibitor.
The AKT inhibitor ipatasertib was not pursued in prostate cancer despite some positive signals in trials. The key reasons were not a complete lack of efficacy, but rather that the magnitude of the benefit was too small and was not supported by improvements in crucial secondary endpoints like overall survival or quality of life, which are needed for regulatory approval and clinical adoption.